5 completed, 4 terminated, 1 recruiting, 1 unknown. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 5, Terminated 4, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Menarini Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections Delafloxacin, Vancomycin, Linezolid - Surgical Site Infection | Phase 3 | Terminated | Menarini Group | 268 | 2019-09-25 | 2022-02-02 |
| Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer Active CTC Assessment - Adenocarcinoma of the Prostate | Phase 3 | Terminated | Institute of Cancer Research, United Kingdom | 12 | 2017-01-11 | 2021-01-06 |
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) Ibodutant 10 mg, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Withdrawn | Menarini Group | 2015-10-01 | 2016-05-19 | |
| 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) Ibodutant 10 mg, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Completed | Menarini Group | 535 | 2014-03-01 | 2017-01-19 |
| 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) Ibodutant 10 mg, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 3 | Terminated | Menarini Group | 558 | 2014-02-01 | 2017-03-03 |
| Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride Placebo, Dexketoprofen-single dose, Tramadol-single dose - Acute Pain | Phase 3 | Completed | Menarini Group | 606 | 2013-05-01 | 2016-04-01 |
| Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride Placebo, Tramadol-single dose, Dexketoprofen-single dose - Acute Pain | Phase 3 | Completed | Menarini Group | 641 | 2013-04-01 | 2016-03-07 |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies Febuxostat, Allopurinol - Tumor Lysis Syndrome | Phase 3 | Completed | Menarini Group | 346 | 2012-10-01 | 2014-11-03 |
| Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients Losartan and nebivolol, Losartan, Nebivolol - Marfan Syndrome | Phase 3 | Unknown | Fondazione IRCCS Policlinico San Matteo di Pavia | 291 | 2008-07-01 | 2011-07-22 |
| Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension OM 40, OM/HCTZ 40/12.5 - Hypertension | Phase 3 | Completed | Menarini Group | 1004 | 2007-07-01 | 2021-07-28 |
| Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients Abagovomab, Placebo - Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Menarini Group | 888 | 2006-12-01 | 2011-11-24 |
Diarrhea (3) · Intestinal Diseases (3) · Irritable Bowel Syndrome (3) · Acute Pain (2) · Pain, Postoperative (2) · Breast Neoplasms (1) · Camurati-Engelmann Syndrome (1) · Hypertension (1) · Infections (1) · Leukemia (1) · Lymphoma (1) · Marfan Syndrome (1) · Ovarian Neoplasms (1) · Surgical Wound Infection (1) · Tumor Lysis Syndrome (1)
Sugars (3) · ibodutant (3) · dexketoprofen trometamol (2) · 6-methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide (1) · Allopurinol (1) · Anastrozole (1) · Febuxostat (1) · Letrozole (1) · Linezolid (1) · Losartan (1) · Nebivolol (1) · Piperacillin, Tazobactam Drug Combination (1) · Tamoxifen (1) · Therapeutics (1) · Tigecycline (1)
Germany (6) · Italy (6) · Poland (6) · Czechia (5) · Spain (5) · Hungary (4) · France (3) · Latvia (3) · Romania (3) · United Kingdom (3) · United States (3) · Belgium (2) · Lithuania (2) · Russia (2) · Slovakia (2)
Andrew Moore, Professor (2) · Henry J McQuay, Professor (2) · Lin Chang, Professor (2) · Angela Capriati, MD, PhD (1) · Anna Pluzanska, MD (1) · Antonio Casado, MD (1) · Eloisa Arbustini, MD,FESC,FACC (1) · Emmanouil Saloustros (1) · Eric Pujade-Lauraine, MD (1) · Giovanni Scambia, MD (1) · Jacobus Pfisterer, MD (1) · Jan F Tack, Prof. (1) · Jan F Tack, Professor (1) · Jan Tack, Professor (1) · Johann De Bono, MBChB FRCP MSc PhD (1)
PMID 16601194, PMID 17188619, PMID 17911499, PMID 19430350, PMID 20593911, PMID 23478059, PMID 24952307, PMID 26216382, PMID 26787797, PMID 26801905, PMID 40908975
2018 (1)